These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 22316275

  • 21. The impact of response on bone-directed therapy in patients with multiple myeloma.
    Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, Gregory WM, Brioli A, Owen RG, Drayson MT, Wu P, Palumbo A, Boccadoro M, Davies FE, Morgan GJ.
    Blood; 2013 Oct 24; 122(17):2974-7. PubMed ID: 23974194
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
    Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M.
    Clin Breast Cancer; 2010 Aug 01; 10(4):267-74. PubMed ID: 20705558
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
    Joshi AD, Carter JA, Botteman MF, Kaura S.
    Clin Ther; 2011 Mar 01; 33(3):291-304.e8. PubMed ID: 21600384
    [Abstract] [Full Text] [Related]

  • 24. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
    Henk HJ, Teitelbaum A, Perez JR, Kaura S.
    Am J Hematol; 2012 May 01; 87(5):490-5. PubMed ID: 22454220
    [Abstract] [Full Text] [Related]

  • 25. Zoledronic acid for all patients with newly diagnosed multiple myeloma?
    Terpos E, Dimopoulos MA.
    Lancet Oncol; 2011 Aug 01; 12(8):711-2. PubMed ID: 21771569
    [No Abstract] [Full Text] [Related]

  • 26. The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.
    Berenson JR.
    Clin Lymphoma Myeloma Leuk; 2012 Feb 01; 12(1):2-4. PubMed ID: 22130220
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E.
    Bone; 2014 Feb 01; 59():105-13. PubMed ID: 24231131
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
    Clin Breast Cancer; 2012 Aug 01; 12(4):247-58. PubMed ID: 22694824
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
    Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown JE, Chakraborti P, Hussain SA, Russell JM, Billingham LJ, James ND.
    BJU Int; 2017 Apr 01; 119(4):522-529. PubMed ID: 27256016
    [Abstract] [Full Text] [Related]

  • 32. Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil.
    Cunio Machado Fonseca M, Tannus Branco de Araújo G, Etto H, Schiola A, Santoni N, Machado M.
    Clin Ther; 2011 Nov 01; 33(11):1769-1780.e2. PubMed ID: 22019346
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
    Logman JFS, Heeg BMS, Botteman MF, Kaura S, van Hout BA.
    Ann Oncol; 2010 Jul 01; 21(7):1529-1536. PubMed ID: 19955334
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
    Paterson A, McCloskey E, Redzepovic J, Ott I, Gust R.
    J Int Med Res; 2008 Jul 01; 36(3):400-13. PubMed ID: 18534121
    [Abstract] [Full Text] [Related]

  • 39. Zoledronic acid in myeloma: MRC Myeloma IX.
    Rajkumar SV.
    Lancet; 2010 Dec 11; 376(9757):1965-6. PubMed ID: 21131042
    [No Abstract] [Full Text] [Related]

  • 40. Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
    Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann MW, Thiel FC.
    Onkologie; 2010 Dec 11; 33(7):360-8. PubMed ID: 20631482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.